NIASPAN TITRATION STARTER PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NIASPAN TITRATION STARTER PACK (NIASPAN TITRATION STARTER PACK).
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT-2) and reducing free fatty acid mobilization from adipose tissue via inhibition of lipolysis. It also increases HDL by reducing hepatic clearance of apoA-I.
| Metabolism | Primarily hepatic metabolism via two pathways: conjugation (low-affinity, high-capacity pathway) and amidation (high-affinity, low-capacity pathway). At low doses, amidation by nicotinamide phosphoribosyltransferase (NAMPT) is the major route; at high doses, conjugation with glycine (to nicotinuric acid) predominates. |
| Excretion | Renal: approximately 60-76% of a dose excreted as unchanged drug and metabolites; biliary/fecal: less than 10% |
| Half-life | Terminal elimination half-life is approximately 2-4 hours for immediate-release niacin; for extended-release (Niaspan), it is 2-6 hours. However, the pharmacodynamic effect on lipids may persist beyond plasma elimination due to prolonged receptor interaction. |
| Protein binding | Less than 20% bound to plasma proteins (mainly albumin) at therapeutic concentrations. |
| Volume of Distribution | Approximately 0.3-0.5 L/kg, suggesting distribution into total body water and some tissue binding. |
| Bioavailability | Extended-release tablets: absolute bioavailability is not established due to extensive first-pass metabolism, but systemic exposure (AUC) is approximately 30-60% of an equivalent intravenous dose; food increases bioavailability by 20-30%. |
| Onset of Action | Oral extended-release: lipid-lowering effects are observed within days to weeks, with maximal effect typically seen after 4-8 weeks of continuous dosing. |
| Duration of Action | Oral extended-release: the lipid-lowering effect lasts for the dosing interval (24 hours) with once-daily administration; clinical effects on HDL and triglycerides may persist for weeks after discontinuation. |
Initial: 500 mg orally once daily at bedtime. Titrate: increase by 500 mg every 4 weeks to a maximum of 2000 mg once daily. Maintenance: 1000-2000 mg once daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended in patients with severe renal impairment (GFR < 30 mL/min) or on dialysis due to risk of niacin accumulation. |
| Liver impairment | Contraindicated in patients with active liver disease or unexplained transaminase elevations. In Child-Pugh A or B, use with caution and monitor liver function; no specific dose recommendations. Child-Pugh C: contraindicated. |
| Pediatric use | Safety and efficacy not established in pediatric patients < 16 years; no approved dosing. |
| Geriatric use | No specific dose adjustment; start at low end of dosing range and titrate slowly due to increased risk of adverse effects (e.g., flushing, hypotension) in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NIASPAN TITRATION STARTER PACK (NIASPAN TITRATION STARTER PACK).
| Breastfeeding | Niacin is excreted into human breast milk in small amounts. The M/P ratio is unknown. At therapeutic doses, it is generally considered compatible with breastfeeding. High doses should be used with caution due to potential adverse effects on the infant. Monitor for flushing or gastrointestinal disturbances in the breastfed infant. |
| Teratogenic Risk | Niacin (nicotinic acid) is generally considered to have low teratogenic potential. Animal studies have not shown evidence of fetal harm. There are limited human data; however, niacin is an essential vitamin, and deficiency is associated with adverse pregnancy outcomes. No specific trimester-specific risks are established. Use only if clearly needed and no safer alternative exists. |
■ FDA Black Box Warning
Severe hepatotoxicity, particularly with sustained-release niacin. Acute hepatic necrosis has been reported. Combination with statins increases risk of myopathy/rhabdomyolysis.
| Serious Effects |
Active liver disease or unexplained transaminase elevations, active peptic ulcer disease, arterial hemorrhage, hypersensitivity to niacin or any component of the product, concurrent use with bile acid sequestrants (should be dosed 4-6 hours apart), severe hypotension.
| Precautions | Elevations in liver enzymes (monitor periodically), risk of hepatotoxicity, flushing and pruritus (pretreatment with aspirin may help), activation of peptic ulcer, hyperuricemia/gout, hyperglycemia (may worsen diabetes), orthostatic hypotension, rare cases of atrial fibrillation and other arrhythmias. |
Loading safety data…
| Fetal Monitoring | Monitor liver function tests (LFTs) and serum uric acid levels periodically due to potential for hepatotoxicity and hyperuricemia. In pregnancy, monitor fetal growth and well-being via ultrasound if prolonged use is required. Monitor maternal blood glucose due to increased insulin resistance in pregnancy. |
| Fertility Effects | No known adverse effects on human fertility. Niacin is an essential nutrient; deficiency may impair reproductive function. High doses have not been associated with fertility impairment in animal studies. |